CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.
Randomized controlled trial · Br J Cancer · 2017. Source record refreshed; an explanation has not been reviewed.
About this paper
This page identifies the publication and its source. A checked explanation of its findings is not yet available.
Reading this record
Checking bibliographic metadata does not verify a study’s conclusions or any advice previously linked to it.
Publication details
CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.
Dufies M, Giuliano S, Viotti J et al.
Br J Cancer · 2017
- PubMed ID
- 28850564
- Record checked
A checked publication record confirms source details. It does not verify a health claim or assess the quality of the study. Our approach.
Keep your place in the research.
Save this source or mark it as read.